Literature DB >> 23579967

Treatment of hypertension in obese patients.

Srividya Kidambi1, Theodore A Kotchen.   

Abstract

Obesity is a global pandemic and with its rise, its associated co-morbidities are increasing in prevalence, particularly uncontrolled hypertension. Lifestyle changes should be an anchor for the management of obesity-related hypertension; however, they are difficult to sustain. Drug therapy is often necessary to achieve blood pressure control. Diuretics, inhibitors of the renin-angiotensin system, and dihydropyridine calcium channel blockers are often used as first trio, with subsequent additions of mineralocorticoid receptor antagonists and/or dual alpha/beta blocking agents. While a number of agents are currently available, 50 % of hypertensive patients remain uncontrolled. A number of novel drug and invasive therapies are in development and hold significant potential for the effective management of obesity-related hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23579967     DOI: 10.1007/s40256-013-0008-5

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  5 in total

Review 1.  Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.

Authors:  Rohan Samson; Andrea Qi; Abhishek Jaiswal; Thierry H Le Jemtel; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

2.  Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort.

Authors:  Emily McDonald; D Michal Freedman; Bruce H Alexander; Michele M Doody; Margaret A Tucker; Martha S Linet; Elizabeth K Cahoon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-08       Impact factor: 4.254

3.  Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.

Authors:  Samir Helmy Assaad-Khalil; Robert Najem; Jorge Sison; Asad Riaz Kitchlew; Belong Cho; Kwo-Chang Ueng; Shelley DiTommaso; Abhijit Shete
Journal:  Vasc Health Risk Manag       Date:  2015-01-21

4.  Obesity-associated hypertension is ameliorated in patients with TLR4 single nucleotide polymorphism (SNP) rs4986790.

Authors:  Simon Schneider; Marcus Baumann; Petra Hoppmann; Werner Koch; Stephan Kemmner; Christoph Schmaderer; Lutz Renders; Adnan Kastrati; Karl-Ludwig Laugwitz; Uwe Heemann
Journal:  J Inflamm (Lond)       Date:  2015-10-01       Impact factor: 4.981

5.  Importance of AT1 and AT2 receptors in the nucleus of the solitary tract in cardiovascular responses induced by a high-fat diet.

Authors:  Guilherme F Speretta; Prashant J Ruchaya; Maria A Delbin; Mariana R Melo; Hongwei Li; José V Menani; Colin Sumners; Eduardo Colombari; Mirian Bassi; Débora S A Colombari
Journal:  Hypertens Res       Date:  2019-01-10       Impact factor: 3.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.